Advanced thyroid cancer responds to targeted therapy with sunitinib
A phase 2 clinical trial found that sunitinib significantly improved progression-free survival in patients with advanced differentiated thyroid cancer. The study showed that 83% of patients benefited from treatment, with either tumor shrinkage or slowed disease progression.